Isoniazid News and Research

RSS

Scientists have identified a novel anti-tuberculosis (TB) compound

Scientists at Johnson & Johnson Pharmaceutical Research and Development have identified a novel anti-tuberculosis (TB) compound that works better and faster than the current standard of care in mouse models of TB infection.

14 Dec 2004

Researchers look to make more effective drug treatments for tuberculosis

Tuberculosis isn’t yet making a major comeback in the U.S. but one- third of the world’s population is infected with the disease, and it poses a major danger to health worldwide.

26 Aug 2004

WHO reports on treating tuberculosis in Ukraine

Multidrug-resistant TB (MDR-TB) is the disease caused by TB bacilli that are resistant to at least isoniazid and rifampicin – the two most powerful anti-TB drugs. It results from inconsistent or partial treatment of TB, and develops when public health programmes fail to deliver regular and reliable treatment to TB patients.

12 May 2004